14-3-3 gamma Polyclonal Antibody, AbBy Fluor® 594 Conjugated

Applications

  • IF(IHC-P)
  • IF(IHC-F)
  • IF(ICC)

Predicted Reactivity

  • Human
  • Mouse
  • Rat
  • Dog
  • Sheep
  • Horse
  • Rabbit
  • Zebrafish
Overview
Catalog # bs-12421R-BF594
Product Name 14-3-3 gamma Polyclonal Antibody, AbBy Fluor® 594 Conjugated
Applications IF(IHC-P), IF(IHC-F), IF(ICC)
Predicted Reactivity Human, Mouse, Rat, Dog, Sheep, Horse, Rabbit, Zebrafish
Specifications
Conjugation AbBy Fluor® 594
Host Rabbit
Source KLH conjugated synthetic peptide derived from human 14-3-3 gamma
Immunogen Range 31-130/247
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Storage Condition Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Target
Gene ID 7532
Subcellular location Cytoplasm
Synonyms 14 3 3 protein gamma; 14 3 3 protein gamma subtype; 14 3 3gamma; 14-3-3 protein gamma; 1433G_HUMAN; 3 monooxygenase/tryptophan 5 monooxgenase activation protein gamma polypeptide; KCIP 1; KCIP-1; KCIP1; N-terminally processed; Protein kinase C inhibitor protein 1; Tyrosine 3 monooxygenase/tryptophan 5 monooxygenase activation protein gamma polypeptide; YWHAG.
Background 14-3-3 proteins regulate many cellular processes relevant to cancer biology, notably apoptosis, mitogenic signaling and cell-cycle checkpoints. Seven isoforms comprise this family of signaling intermediates, denoted 14-3-3 b, g, e, z, h, q and s. 14-3-3 proteins form dimers that present two binding sites for ligand proteins, thereby bringing together two proteins that may not otherwise associate. These ligands largely share a 14-3-3 consensus binding motif and exhibit serine/threonine phosphorylation. 14-3-3 proteins function in broad regulation of these ligand proteins; by cytoplasmic sequestration, occupation of interaction domains and import/export sequences, prevention of degradation, activation/repression of enzymatic activity, and facilitation of protein modification. Loss of expression contributes to a vast array of pathogenic cellular activities.
Application Dilution
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200